Skip to main content
Clinical Trials/NCT04704895
NCT04704895
Unknown
Not Applicable

A Prospective RCT Study of Comparing Early Enteral Nutrition Versus Parenteral Nutrition After Pancreaticoduodenectomy

Xian-Jun Yu1 site in 1 country210 target enrollmentFebruary 1, 2021

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Enteral Nutrition
Sponsor
Xian-Jun Yu
Enrollment
210
Locations
1
Primary Endpoint
The percentage of patients with one or more postoperative complications (time range: 90 days) was observed, and data were recorded during the hospital stay (expected average of 3 weeks) and during control visits 3 months postoperatively.
Last Updated
5 years ago

Overview

Brief Summary

To prove that early enteral nutrition after pancreaticoduodenal operation is of great significance to improve the immune response, reduce the incidence of postoperative infection and other related complications, and shorten the length of hospital stay

Detailed Description

Arm A: Total parenteral nutrition. TPN also started from POD 1 and was delivered through a central venous catheter. Target energy of 1.5 amino acids/kg/day reached 30 kcal/kg/day. Arm B: NJEEN was defined as providing at least 50% of the nutritional requirements through the nasojejunal tube prior to the 5th day after surgery (POD) and having no parenteral nutrition for 72 h or more.

Registry
clinicaltrials.gov
Start Date
February 1, 2021
End Date
September 30, 2023
Last Updated
5 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Xian-Jun Yu
Responsible Party
Sponsor Investigator
Principal Investigator

Xian-Jun Yu

President of Pancreatic Cancer Institute

Fudan University

Eligibility Criteria

Inclusion Criteria

  • Age between 18 and 80 years old, gender is not limited;
  • All patients underwent pancreaticoduodenectomy;
  • ECOG 0 \~ 2 for physical condition score;
  • Imaging examination found pancreatic head, periampullary space, no distant metastasis and ascites;
  • No bone marrow dysfunction;
  • Those without obvious surgical contraindications;
  • Expected postoperative survival ≥3 months;
  • The study visit plan and other programme requirements are now available;
  • Voluntary participation and signing of informed consent.

Exclusion Criteria

  • Patients with stage II and IV periampullary carcinoma of head of pancreas and periampullary carcinoma;
  • Active infected persons;
  • Distant metastasis or ascites were found in imaging examination;
  • Patients with serious impairment of heart, liver and kidney function (grade 3 to 4, ALT and/or AST more than 3 times the normal upper limit, Cr more than the normal upper limit);
  • patients with other malignant tumors or blood diseases;
  • Pregnancy, planned pregnancy and lactation female patients (urine HCG \>02500 iu /L, diagnosed as early pregnancy);

Outcomes

Primary Outcomes

The percentage of patients with one or more postoperative complications (time range: 90 days) was observed, and data were recorded during the hospital stay (expected average of 3 weeks) and during control visits 3 months postoperatively.

Time Frame: 3month

The percentage of patients with one or more postoperative complications (time range: 90 days) was observed, and data were recorded during the hospital stay (expected average of 3 weeks) and during control visits 3 months postoperatively.

Study Sites (1)

Loading locations...

Similar Trials